MR 387B
Latest Information Update: 20 Jun 2001
Price :
$50 *
At a glance
- Originator Nonindustrial source
- Class Antineoplastics
- Mechanism of Action Peptide hydrolase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 20 Jun 2001 No-Development-Reported for Cancer in South Korea (Unknown route)
- 25 Nov 1998 New profile
- 25 Nov 1998 Preclinical development for Cancer in South Korea (Unknown route)